Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Biogen reports mixed Phase II results for LINGO antibody

    Biogen Idec Inc. (NASDAQ:BIIB) said BIIB033 did not meet its primary or secondary endpoints in the Phase II RENEW trial to treat acute optic neuritis (AON) but termed the results "encouraging" by providing the first …

    Published on 1/8/2015
  • CLINICAL NEWS: GW's epilepsy timetable eclipses Sativex cancer miss

    Investors ignored a Phase III trial miss for Sativex in cancer pain on Thursday, pushing up shares of GW Pharmaceuticals plc (NASDAQ:GWPH; LSE:GWP) by 13% on NASDAQ after the company said it expects to begin reading out…

    Published on 1/8/2015
  • CLINICAL NEWS: Neurocrine jumps on Phase III endometriosis data

    Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $5.60 (26%) to $27.48 on Thursday after partner AbbVie Inc. (NYSE:ABBV) said elagolix (ABT-620) met its co-primary endpoints in the Phase III M12-665 trial to treat …

    Published on 1/8/2015
  • CLINICAL NEWS: Arena surges on Phase I data for S1PR1 candidate

    Arena Pharmaceuticals Inc. (NASDAQ:ARNA) added $2.53 (76%) to $5.85 on Wednesday, increasing its market cap to $1.3 billion, after reporting top-line results of a Phase Ib study of APD334, a sphingosine 1-phosphate …

    Published on 1/7/2015
  • CLINICAL NEWS: New high for Alkermes on Phase II schizophrenia data

    Alkermes plc (NASDAQ:ALKS) hit a 52-week high on Wednesday, jumping $5.82 (10%) to $66.75 after its ALKS 3831, a combination of olanzapine plus samidorphan, met the primary endpoint of equivalence to olanzapine in …

    Published on 1/7/2015
  • CLINICAL NEWS: Zafgen climbs on Phase II HIAO results

    Zafgen Inc. (NASDAQ:ZFGN) gained $6.65 (21%) to $38.31 after it said beloranib met the primary endpoint of weight reduction in a Phase II trial to treat adults with hypothalamic injury associated obesity (HIAO). In the …

    Published on 1/7/2015
  • CLINICAL NEWS: KaloBios drops CF progam after Phase II miss

    KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The …

    Published on 1/6/2015
  • CLINICAL NEWS: BrainStorm spikes on NurOwn data in ALS

    BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) said a single dose of its NurOwn stem cell therapy slowed at least one measure of disease progression in 11 of 12 of patients in a Phase IIa trial to treat ALS.The company…

    Published on 1/5/2015
  • CLINICAL NEWS: Cempra looking for $100M on back of solithromycin data

    Cempra Inc. (NASDAQ:CEMP) said its oral solithromycin (CEM-101) met the primary endpoint in the Phase III Solitaire-Oral trial to treat community acquired bacterial pneumonia (CABP) and proposed to raise up to $100 …

    Published on 1/5/2015
  • CLINICAL NEWS: Achillion gains on HCV data

    Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) gained $1.28 to $15.49 on Monday after it said 100% of patients receiving ACH-3102 plus Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD) achieved an SVR4 after six …

    Published on 12/22/2014
  • CLINICAL NEWS: Radius jumps on Phase III osteoporosis data

    Radius Health Inc. (NASDAQ:RDUS) gained $5.42 (17%) to $37.45 after abaloparatide-SC met the primary endpoint of a Phase III study to reduce fractures in postmenopausal osteoporosis.In the ACTIVE trial, abaloparatide-SC…

    Published on 12/22/2014
  • CLINICAL NEWS: Roche down on Phase III setbacks

    Roche (SIX:ROG; OTCQX:RHHBY) fell CHF18.30 to CHF270.40 on Friday after reporting disappointing data from a Phase III trial of breast cancer drug Kadcyla ado-trastuzumab emtansine and discontinuing a Phase III study of …

    Published on 12/19/2014
  • CLINICAL NEWS: GSK, Agenus shingles vaccine meets primary endpoint

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said its HZ/su herpes zoster vaccine (GSK1437173A) met the primary endpoint of reducing the risk of shingles by 97.2% in people aged 50 and older vs. placebo in the Phase III ZOE-…

    Published on 12/18/2014
  • CLINICAL NEWS: Tetraphase climbs on Phase III cIAI data

    Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) jumped $4.81 (14%) to $38 on Thursday after IV eravacycline met the primary endpoint in the Phase III IGNITE 1 trial to treat complicated intra-abdominal infection (cIAI). …

    Published on 12/18/2014
  • CLINICAL NEWS: Well-traveled desmoteplase finally hits the wall

    H. Lundbeck A/S (CSE:LUN) said it will cease development of desmoteplase (DPSA) to treat acute ischemic stroke.The compound, which has been in development for more than a decade and failed a Phase III study in 2007, …

    Published on 12/17/2014
  • CLINICAL NEWS: ALA to promote Lung-MAP

    The American Lung Association said it will promote the Lung-MAP project, a "master protocol" trial designed to evaluate several compounds simultaneously to treat squamous cell lung cancer.Under a partnership with the …

    Published on 12/16/2014
  • CLINICAL NEWS: Cyclacel plummets on futility analysis

    Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) dropped $2.15 (76%) to $0.68 after oral sapacitabine (CYC682) failed a futility analysis of survival in a Phase III trial to treat acute myelogenous leukemia (AML).The Data …

    Published on 12/16/2014
  • CLINICAL NEWS: Alnylam outlines R&D strategy

    At its R&D day on Friday, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) refined its focus on developing RNAi therapeutics across three areas: hepatic infectious disease, genetic medicines and cardiometabolic disease. The …

    Published on 12/12/2014
  • CLINICAL NEWS: Plexxikon's PLX3397 to join I-SPY 2

    Plexxikon Inc. said its PLX3397 will be included in the Phase II I-SPY 2 trial to treat patients with newly diagnosed, locally advanced breast cancer. PLX3397 will enter the ongoing trial, which is managed by …

    Published on 12/11/2014
  • CLINICAL NEWS: Brexpiprazole meets primary in Phase III depression trial

    H. Lundbeck A/S (CSE:LUN) and Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) said all three doses of once-daily brexpiprazole (OPC-34712) met the primary endpoint in two Phase III trials to treat major depressive …

    Published on 12/10/2014
  • CLINICAL NEWS: First look: Genentech vs. Merck in triple-negative

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) and Merck & Co. Inc. (NYSE:MRK) unveiled interim Phase I data for their targeted PD-1 compounds against triple-negative breast cancer (TNBC), with the former …

    Published on 12/10/2014
  • CLINICAL NEWS: Naurex heads for Phase III on unexpected results

    Naurex Inc. (Evanston, Ill.) intends to begin a Phase III trial next year of GLYX-13 as an adjunctive therapy to treat major depressive disorder (MDD) even though the compound missed the primary endpoint of a Phase IIb …

    Published on 12/10/2014
  • CLINICAL NEWS: Competing Hodgkin's presentations at ASH

    Shares of Seattle Genetics Inc. (NASDAQ:SGEN) recovered much of their losses, closing up $1.83 to $35.36 on Tuesday after dipping $2.57 to $33.53 on Monday amid competitive presentations in Hodgkin's lymphoma at the …

    Published on 12/9/2014
  • CLINICAL NEWS: Acceleron gains on interim luspatercept data

    Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corp. (NASDAQ:CELG) reported interim data from an open-label Phase II trial of luspatercept (ACE-536) to treat beta thalassemia intermedia. The modified activin receptor …

    Published on 12/8/2014
  • CLINICAL NEWS: Amgen reports more Kyprolis data

    Amgen Inc. (NASDAQ:AMGN) for the first time reported data from secondary endpoints in the Phase III ASPIRE trial of Kyprolis carfilzomib plus Revlimid lenalidomide and low-dose dexamethasone to treat relapsed multiple …

    Published on 12/8/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993